chapter  55
8 Pages

Anti-EGFR nimotuzumab for DIPG in recurrent or children with high grade glioma: 10 years

WithU. Bone, R. Cabanas, G. Saurez-Martinez, T. Crombet Ramos, P. Lorenzo-Luaces, M. Massimino, U. Bartels, E. Bouffet, F. Bach, D. Reuter, R.A. Ilyas, R. Ellerson, N. Iznaga-Escobar

You have download access for this chapter.

PDF 0.08MB

Children glioma is a life-threatening condition with a survival rate of less than one year. Nimotuzumab, a unique and affinity differentiated anti-EGFR antibody for the past ten years had been used in combination with radiotherapy or radiochemotherapy. The aim of these studies was to evaluate nimotuzumab in combination with radiotherapy or radiochemotherapy in newly diagnosed children with DIPG. Patients received i.v. infusions of 150 mg/m2 of nimotuzumab in combination with 54 Gy radiotherapy or radiochemotherapy for DIPG patients or 150 mg/m2 of nimotuzumab as monotherapy on high-grade glioma, weekly, for 6-8 weeks, and then every 2-3 weeks until disease progression or unacceptable toxicity. A total of 87 newly diagnosed children with DIPG (35 male/52 female), median age 7.6 yr old were recruited. Use of nimotuzumab had been efficacious in newly diagnosis children with DIPG and recurrent or refractory children with high-grade glioma. Keywords: anti-EGFR, nimotuzumab, DIPG